Mon travail de thèse porte sur les épilepsies focales avec ou sans malformations cérébrales de type dysplasie corticale focale. Il s'articule autour de (1) une étude fonctionnelle et génétique sur tissu cérébral postopératoire humain et (2) la caractérisation d'un nouveau modèle génétique chez l'animal. Tout d'abord, des mutations germinales hétérozygotes perte de fonction ont été identifiées dans DEPDC5, NPRL2 et NPRL3 qui codent pour le complexe GATOR1, un inhibiteur du complexe 1 de mTOR (mTORC1). Par la suite, des mutations somatiques cérébrales gain de fonction ont été identifiées dans MTOR. Nous avons émis l'hypothèse que ces mutations entrainent une hyperactivité de mTORC1, responsable des malformations cérébrales et de l'épilepsie des patients. J'ai observé une hyperactivité de mTORC1 dans les cellules cytomégaliques obtenues à partir de tissu cérébral post-opératoire de patients porteurs de mutations dans les gènes de GATOR1 ou MTOR. En parallèle, la caractérisation du premier modèle KO de Depdc5 a montré que les rats Depdc5+/- présentent des anomalies corticales rappelant celles des patients : délamination des couches corticales et cellules cytomégaliques avec une hyperactivité de mTORC1. Ce phénotype est prévenu par l'injection de rapamycine, un inhibiteur spécifique de mTORC1. Une susceptibilité accrue aux crises épileptiques induites par le pentylènetétrazole ainsi qu'un défaut des propriétés neuronales passives et actives ont été rapportés chez les rats Depdc5+/-. En conclusion, mes travaux de thèse ont contribué à mettre en évidence l'implication de la voie GATOR1-mTORC1 dans les épilepsies et dysplasies corticales focales. / In my PhD thesis work, I investigated focal epilepsies with and without brain malformations such as focal cortical dysplasia. I focused on two complementary aspects: (1) genetics and functional studies on human tissue samples and (2) characterization of a novel genetic animal model. First, germline heterozygous loss-of-function mutations were identified in DEPDC5, NPRL2 and NPRL3 genes that encode proteins which together form the GATOR1 complex, a repressor of the mTOR complex 1 (mTORC1). Additionally, brain somatic gain-of- function mutations were identified in MTOR gene that encodes mTOR itself. Both types of mutations are thought to lead to mTORC1 hyperactivity, and cause brain malformation and epilepsy in patients. To test this hypothesis, mTORC1 activity was monitored on post-operative brain tissue from patients carrying GATOR1 or mTOR genes mutations. Cytomegalic cells with mTORC1 hyperactivity were observed. Besides, the characterization of the first Depdc5 KO model revealed that Depdc5+/- rats present cortical structural abnormalities reminiscent of patient histopathology hallmarks: cortical layer dyslamination and cytomegalic cells with increased mTORC1 activity. This phenotype was prevented by rapamycin injection, a specific mTORC1 inhibitor. An increased susceptibility to pentylenetetrazol-induced epileptic seizures, as well as impaired passive and active neuronal properties were observed in Depdc5+/- rats compared to Depdc5+/+ rats. In conclusion, my PhD work largely contributed to emphasize the prominent role of the GATOR1-mTORC1 pathway in focal cortical dysplasia and epilepsies.

Submitted by LUIS GABRIEL RIVERA CALDERON (lgriveramvz@gmail.com) on 2018-05-02T17:50:21Z No. of bitstreams: 1 Tese_Luis_Gabriel_Rivera_Calderon.pdf: 12272198 bytes, checksum: 78d4519bb4d6661c6d6284b28f290374 (MD5) / Rejected by Alexandra Maria Donadon Lusser Segali null (alexmar@fcav.unesp.br), reason: Solicitamos que sejam feitas as correções listadas abaixo: O arquivo PDF submetido no repositório deve conter ficha catalográfica e certificado de aprovação (documentos obrigatórios). Favor inserir os mesmos no arquivo PDF e fazer novamente a submissão. Agradecemos a compreensão. on 2018-05-02T18:50:24Z (GMT) / Submitted by LUIS GABRIEL RIVERA CALDERON (lgriveramvz@gmail.com) on 2018-05-03T11:50:35Z No. of bitstreams: 1 Tese Luis Gabriel Rivera.pdf: 12908129 bytes, checksum: a2bb73ad103cbc2de776d2b460919a3c (MD5) / Approved for entry into archive by Alexandra Maria Donadon Lusser Segali null (alexmar@fcav.unesp.br) on 2018-05-04T18:04:24Z (GMT) No. of bitstreams: 1 riveracalderon_lg_dr_jabo.pdf: 12908129 bytes, checksum: a2bb73ad103cbc2de776d2b460919a3c (MD5) / Made available in DSpace on 2018-05-04T18:04:24Z (GMT). No. of bitstreams: 1 riveracalderon_lg_dr_jabo.pdf: 12908129 bytes, checksum: a2bb73ad103cbc2de776d2b460919a3c (MD5) Previous issue date: 2018-03-26 / Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) / O câncer é uma doença complexa que precisa de um microambiente favorável para seu crescimento e progressão. Esse microambiente tumoral esta constituido por células neoplásicas, vasos sanguíneos, células imunes, fibroblastos e a matriz extracellular (MEC). Geralmente, as células neoplásicas apresentam modificações nas suas vias de sinalização. No homem, a via mTOR/4E-BP1/eIF4E foi descrita como alterada em diferentes tumores, incluindo o câncer de próstata (CP).Além do homem, o cão é espécie doméstica que desenvolve com mais frequência o CP, sendo considerada um potencial modelo para estudos na área de Oncologia Comparada. Devido à limitada informação sobre a via mTOR/4E-BP1/eIF4E e os componentes da MEC nos CP caninos, o objetivo deste estudo foi avaliar a expressão gênica e protéica de mTOR, 4E-BP-1 e eIF4E neste tipo de tumor. Outrossim, avaliar a expressão dos colágenos (C-I e C-III) pela técnica Picrosirius (PSR) e imuno-histoquímica no tecido prostático normal e neoplásico. Foram utilizadas 35 amostras de tecido prostático caninos. Identificou-se alta expressão protéica de p-mTOR e eIF4E nos CP caninos com alto GS (≥ 8), assim como, correlação positiva entre essas proteínas. Nos colágenos não foi observada diferença de expressão quando comparadas amostras de próstata normal e CP canino. De forma similar com o CP humano, estes resultados sugerem que p-mTOR e eIF4E podem ser bons marcadores para o processo carcinogênico prostático canino e estão correlacionados com alto GS. Além disso, a distribuição de colágenos foi similar no tecido prostático normal e neoplásico. / Cancer is a complex disease that needs a favorable microenvironment for its growth and progression. This tumor microenvironment consists of neoplastic cells, blood vessels, immune cells, fibroblasts and extracellular matrix (ECM). Generally, neoplastic cells show modification in their signaling pathways. In men, the mTOR/4EBP1/eIF4E pathway has been described as altered in different tumors, including prostate cancer (PC). Apart from men, the dog is the only species that develops with high frequency the PC, being considered a potential model for comparative oncology initiatives. Due to limited information on this pathway and ECM components in canine tumors, this study aimed to investigate mTOR, 4E-BP1 and eIF4E gene and protein expression in canine PC. Additionally, to evaluate the expression of collagens (C-I and C-III) by Picrosirius Red and Immunohistochemistry in normal samples and canine PC. Were used a total of 35 formalin-fixed paraffin-embedded (FFPE) samples from canine prostatic tissue. We identified higher p-mTOR and eIF4E protein levels in the canine PC with higher GS (≥ 8), as well as, significant positive correlation between these proteins. No difference statistical was observed in the collagen expression between normal samples and canine PC. Similar to human PC; our data suggested that p-mTOR and eIF4E good markers for canine prostatic carcinogenic process and are correlated with higher GS. Also, the distribution and collagen levels are similar in normal and neoplastic canine prostate. / 443884/2014-5

Les léiomyosarcomes (LMS) sont des tumeurs d’origine mésenchymateuse caractérisées par une différenciation musculaire lisse. La voie de signalisation PI3K/mTOR (qui contrôle la prolifération et la survie cellulaire) joue un rôle majeur dans le développement de ces tumeurs. De nos jours, cette voie est devenue une cible thérapeutique majeure en oncologie. Cette étude est la première qui évalue le bénéfice thérapeutique de l’inhibition de la voie PI3K/mTOR pour des patients atteint de LMS. Nous avons mis en évidence qu’une double inhibition de PI3K et mTOR est associée à une activité antitumorale supérieure à celle observée avec une inhibition de PI3K ou mTOR seule. Nous avons également montré que l’inhibition de la voie PI3K/mTOR est associée à une activation paradoxale de la voie MAPK et qu’un ciblage concomitant de cette voie est associé à une synergie antitumorale in vitro et in vivo. Afin de caractériser les mécanismes de résistance secondaire à l’inhibition de la voie PI3K/mTOR, nous avons développé in vitro et in vivo un modèle de résistance secondaire à l’inhibiteur double cible PI3K/mTOR. Nous avons notamment détecté une sous-population de cellules résistantes à l’inhibiteur et ayant des caractéristiques proches de celles des cellules souches. Nous avons mis en évidence que l’inhibition pharmacologique d’EZH2, une protéine cruciale du complexe Polycomb, permet de restaurer la sensibilité des modèles résistants. Ces résultats apportent de nouvelles perspectives thérapeutiques pour les patients atteints de LMS. / Leiomyosarcomas (LMS) are tumors of mesenchymal origin characterized by a smooth cell differentiation. The PI3K/mTOR pathway has been shown to play a crucial role in the tumorigenesis of LMS. Several agents targeting this pathway are under clinical development for the treatment of solid tumors and hematological malignancies. We report here the first study evaluating its potential therapeutic benefit for patients with LMS. We have demonstrated that dual inhibition of PI3K and mTOR is associated with more effective antitumor activity than agents targeting PI3K or mTOR only. We have also shown that PI3K and mTOR inhibition is associated with a paradoxal activation of the MAPK pathway and that combined treatment with MEK inhibitor resulted in synergistic antitumor activity in vitro and in vivo. Moreover, we developed in vitro and in vivo resistant model to dual PI3K/mTOR inhibitor. Interestingly, we have found that a cancer stem cell-like subpopulation may be involved in treatment resistance. We have shown that pharmacological inhibition of EZH2, a crucial protein of the Polycomb complex, is able to reverse dual PI3K/mTOR inhibitor resistance in vitro and in vivo. These results provide new therapeutic strategies for patients with LMS.

Recentemente suspeitas de que mecanismos epigenéticos poderiam estar relacionados à fisiopatologia da depressão foram levantadas. Estudos recentes indicam que as alterações na transcrição gênica, induzidas por estresse ou por drogas antidepressivas, parecem envolver mecanismos epigenéticos. Nesse sentido, resultados preliminares de nosso grupo de pesquisa indicaram pioneiramente inibição global da metilação de DNA através da administração sistêmica do agente inibidor da DNA metiltransferase (DNMTs), 5-aza-2-deoxicitidina (5-azaD), induz efeito tipo-antidepressivo, dose-dependente, no modelo animal do nado forçado em ratos(Sales et al., 2011). O córtex pré-frontal medial ventral (CPFMv) é uma estrutura límbica intimamente relacionada com a neurobiologia da depressão. Evidências recentes indicam que o efeito tipo-antidepressivo aparece associado a aumento dos níveis da neurotrofina BDNF (brain derived neurotrophic factor) e de seu receptor TrkB no CPFMv, sendo a sinalização intracelular mediada pela ativação da proteína m-TOR. Contudo, não há evidências de que esses mecanismos moleculares estariam envolvidos nos efeitos induzidos pelos inibidores da metilação do DNA. Sabe-se, no entanto, que tanto o BDNF quanto TrkB têm sua expressão regulada por metilação do DNA. Diante disso, o objetivo presente trabalho será investigar a participação da via BDNF-TrkB-mTOR do CPFMv no efeito antidepressivo induzido por inibidores da metilação de DNA. Para tanto, ratos tratados com inibidores da metilação de DNA (5-azaD ou RG-108), em dois momentos diferentes (imediatamente após o PT e 23horas após o PT) foram submetidos ao teste do nado forçado (FST). Outro grupo de animais recebeu uma injeção intra-CPMv de k252a ou Rapamicina, 40 minutos antes do teste e uma injeção de BDNF intra-CPFMv, 30 minutos antes do teste. Em outro experimento, grupos independentes de animais submetidos ao nado forçado foram tratados sistemicamente com RG-108 e receberam injeção intra-CPFMv de K252a (antagonista de Trk) ou de rapamicina (inibidor da m-Tor), a fim de investigar se o efeito dessas drogas depende da via BDNF-TrkB-mTOR no CPFMv. Um grupo independente foi tratado com RG108 e CPFM desses animais foi dissecado para posterior análise da expressão de BDNF, TrkB e m-TOR, bem como da metilação de DNA. O tratamento com RG108 e 5azaD sistêmico reduziu o tempo de imobilidade dos animais submetidos ao nado forçado nos dois tempo de administração. A administração intra-CPFMv de BDNF promoveu efeito antidepressivo no FST, e esse efeito foi bloqueado pela administração de k252a ou Rapamicina no CPFMv. No mesmo sentido, o efeito antidepressivo do RG108 sistêmico foi bloqueado pela administração intra-CPFMv de k252a ou Rapamicina. Entretanto, a medida dos níveis de metilação global no CPFMv não apresentou alteração como tratamento com RG108, e também não mostrou alteração nos níveis de BDNF presente no CPF. O tratamento com RG108 não alterou a expressão, bem como a ativação de TRkB e mTOR. Concluímos que os inibidores da metilação do DNA apresentam agudamente efeito tipo antidepressivo rápido, que necessita da funcionalidade integral da via BDNF-TRkB-mTOR. Entretanto, esse efeito parece não alterar a síntese e expressão das proteínas envolvidas nessa via no que diz respeito ao CPFmv. / Recent studies indicate that changes in gene transcription induced by stress or antidepressant drugs appear to involve epigenetic mechanisms. Accordingly, results of our research group pioneered indicated global inhibition of DNA methylation through systemic administration of an inhibitor of DNA methyltransferase (DNMTs), 5-aza-2-deoxycytidine (5-AzaD), induces antidepressant-like effect dose-dependent in the animal model of forced swimming in rats (Sales et al., 2011). The ventral medial prefrontal (vmPFC) cortex is a limbic structure closely related to the neurobiology of depression. Recent evidence indicates that the antidepressant-like effect appears associated with increased levels BDNF (Brain derived neurotrophic factor) and its receptor TrkB in vmPFC, and intracellular signaling mediated by activation of protein mTOR. However, there is no evidence that these molecular mechanisms are involved in the effects induced by inhibitors of DNA methylation. It is known, however, both as BDNF and TrkB expression is regulated by DNA methylation. Thus, the goal of this work is to investigate the role of BDNF-TRkB pathway mTOR-vmPFC in the antidepressant effect induced by inhibitors of DNA methylation. To this end, rats treated with inhibitors of DNA methylation (5-Azad or RG-108), at two different times (immediately after 23hours after the PT and PT) were subjected to the forced swim test (FST). Another group received an intra-vmPFC injection of K252a or Rapamycin 40 minutes before the test, and an injection intra-vmPFC of BDNF 30 minutes before the test. In another experiment, separate groups undergoing the forced swim were treated systemically with RG-108 and received intra-vmPFC of K252a (Trk antagonist) or injection of rapamycin (m-Tor inhibitors) in order to investigate the effect these drugs depends on BDNF-TrkB-mTOR pathway in vmPFC. A separate group was treated with RG108 and mPFC these animals were dissected for analysis of the expression of BDNF and TrkB m-TOR, as well as DNA methylation. The systemic treatment whit 5azaD and RG108 reduced the immobility time of rats subjected to FST administration in both time. The intra-vmPFC BDNF administration promoted antidepressant effect in the FST, and this effect was blocked by the administration of K252a or Rapamycin in vmPFC. Similarly, the antidepressant effect of systemic RG108 was blocked by intra-vmPFC of K252a or Rapamycin administration. However, the measurement of the levels of global methylation in CPFMv did not change as treatment with RG108, and also showed no change in the levels of BDNF present in the CPF. Treatment with RG108 did not alter the expression and activation of TrkB and mTOR. We conclude that inhibitors of DNA methylation present acutely antidepressant-like effect, it needs the full functionality of the BDNF-TrkB-mTOR pathway. However, this effect seems not to alter the synthesis and expression of proteins involved in this pathway at vmPFC.

O efeito da hipertrofia induzida por sobrecarga funcional no músculo extensor digital longo (EDL) e sóleo de ratos diabéticos induzidos por estreptozotocina foi avaliado. Ratos Wistar foram induzidos ao estado diabético por dose única de estreptozotocina (65mg/kg peso corporal, i.v.) e mantidos nessa condição durante quatro semanas. Foi então realizada tenotomia do músculo gastrocnêmio ou ablação do músculo tibial anterior. Os conteúdos de Akt e S6 totais e fosforiladas foram avaliados após uma e quatro semanas de sobrecarga nos músculos EDL e sóleo. No EDL, após 7 dias de sobrecarga, ocorreu aumento de fosfo-Akt, fosfo-S6 e S6 total no músculo EDL nos grupos diabético e controle. Os aumentos foram semelhantes entre os grupos. No músculo sóleo, os conteúdos de Akt total e fosfo-Akt aumentaram significativamente, após 7 dias de sobrecarga funcional. A área da secção transversa das fibras, a massa, as forças tetânica e isotônica, absolutas e específicas foram avaliadas nos músculos sóleo e EDL após 4 semanas de sobrecarga e apresentaram aumentos similares em resposta à sobrecarga funcional. A deficiência de insulina por até 4 semanas não afeta de modo significativo a resposta hipertrófica induzida por sobrecarga funcional nos músculos sóleo e EDL de ratos. / The effect of hypertrophy induced by functional overload on extensor digitalis longus (EDL) and soleus muscles of streptozotocin-induced diabetic rats were evaluated. Male Wistar rats were rendered diabetic by a single dose of streptozotocin (65mg/kg b.w., i.v.) and maintained under this condition for four weeks. Then, tenotomy of the gastrocnemius muscle or tibialis anterior ablation were performed. Contents of total and phosphorylated Akt and S6 were evaluated after one and four weeks of overload on EDL and soleus muscles. Phospho-Akt content was increased in control and diabetic animals in hypertrophied muscles. Contents of phospho-S6 and total S6 increased after 7 days of overload either in the control and diabetic groups. In soleus muscle, after 7 days of overload, increases in contents of total Akt and phospho-Akt were observed. Content of phospho-S6 was increased in diabetic group. Fiber cross-sectional area (CSA), muscle mass, and tetanic forces were evaluated after four weeks of overload. Increases in muscle mass and CSA were observed in EDL and soleus muscles of diabetic and control rats. Deficiency of insulin for up to 4 weeks has no significant effect on the hypertrophic response induced by functional overload on the EDL and soleus muscles.

A redução no desenvolvimento muscular de filhotes cujas mães foram submetidas ao consumo de dietas baseadas no padrão ocidental pode ser, ao menos em parte, explicada pela resistência periférica à insulina, condição na qual a atividade de proteínas relacionadas à via de sinalização intracelular sensível a esse hormônio encontra-se reduzida. A regulação positiva dessa via resulta no aumento da atividade do Alvo da Rapamicina em Mamíferos (mTOR) que atua como efetor positivo da taxa de tradução de RNAm e, consequentemente, da síntese proteica. Estudos que avaliam a atividade dessa proteína frente ao consumo crônico de dietas hiperlipídicas são escassos e controversos e, até o momento, não são conhecidos trabalhos que avaliaram esses marcadores em animais neonatos ou desmamados, provenientes de mães alimentadas com dieta hiperlipídica gestacional e pós-gestacional. O presente estudo objetiva avaliar o efeito do consumo de uma dieta hiperlipídica por ratas adultas sobre a morfologia e sobre a expressão e a fosforilação das proteínas que compõem a via de sinalização intracelular do mTOR no músculo esquelético da prole em dois momentos: nascimento e desmame. Para isso, inicialmente, 39 ratas foram distribuídas em dois grupos, de acordo com a dieta oferecida: controle (n=19) e hiperlipídica (n=20). Após o nascimento, cerca de seis filhotes por mãe foram eutanasiados para coleta de amostras e análise dos marcadores investigados. Os filhotes selecionados para dar continuidade ao experimento foram dispostos junto às mães que, por sua vez, foram distribuídas em outros quatro grupos, segundo a dieta gestacional e pós-gestacional: CON/CON (n=8); CON/HL (n=9); HL/HL (n=8); HL/CON (n=7). Ao final da lactação, os filhotes foram eutanasiados e amostras foram coletadas para análise. Os resultados obtidos indicam que, em relação aos animais neonatos, há redução das concentrações séricas de leptina e de IGF-I e aumento da fosforilação da Akt e do mTOR musculares, em resposta ao consumo materno da dieta hiperlipídica. Por sua vez, nos animais lactentes, observamos influência da dieta hiperlipídica materna pós-gestacional sobre a promoção de fenótipo obesogênico, com concomitante redução do desenvolvimento muscular e da fosforilação de proteínas alvo do mTOR em estado pós-prandial. Com base nos resultados obtidos, concluímos que a dieta hiperlipídica materna afeta a atividade do mTOR, sendo, esse efeito, dependente da idade e da condição fisiológica dos animais. / The decrease in muscle development of offspring whose mothers consume a typical Western diet can be partly explained by the progression of peripheral insulin resistance, a condition in which the activity of proteins related to the intracellular signaling pathway sensitive to this hormone is reduced. The positive regulation of this pathway results in increased activity of the Mammalian Target of Rapamycin (mTOR) that acts as a positive regulator of the rate of mRNA translation and protein synthesis. Studies that assess the activity of this protein in response to chronic consumption of high fat diets are scarce and controversial and, to date, studies that evaluated these markers in the offspring of mothers fed a high fat diet during gestational and lactation are not known. This study aims to evaluate the effect of consuming a high fat diet for female adult rats in morphology and expression and phosphorylation of proteins that comprise the intracellular signaling pathway of mTOR in skeletal muscle of offspring in two stages: birth and weaning. Therefore, initially, 39 rats were divided into two groups, according to the available diet: control (n = 19) and diet (n = 20). After birth, around six pups per mother were killed for sample collection and analysis of the markers investigated. The pups selected to continue the experiment were placed with the mothers who, in turn, were divided into four groups according to gestational and post-gestational diets: CON/CON (n = 8), CON/HL (n = 9), HL/HL (n = 8), HL/CON (n = 7). At the end of lactation, the pups were euthanized and samples were collected for analysis. The results indicate that, for the newborn animals, there is a reduction of serum leptin and IGF-I concentrations and increased phosphorylation of Akt and mTOR in muscle in response to maternal consumption of high fat diet. In turn, we found that maternal high-fat diet during lactation promoted an obese phenotype in weaned animals, with concomitant reduction of muscle development and mTOR target proteins phosphorylation in the postprandial state. Based on these results, we conclude that maternal high-fat diet affects the activity of mTOR, depending on age and physiological condition of the animals.

A arginina é um aminoácido condicionalmente essencial que participa de inúmeras reações metabólicas no organismo como, por exemplo, o ciclo da uréia, a síntese de creatina e a geração de óxido nítrico (NO). Além dessas funções a arginina é associada, com a sensibilidade à insulina, a secreção de GH e mais recentemente com a síntese protéica muscular. O objetivo deste trabalho foi investigar o efeito da suplementação via oral crônica de L-arginina sobre a síntese protéica muscular, pela via da mTOR, a fim de contribuir com as novas discussões científicas acerca deste aminoácido de ampla atuação. Métodos: Foram utilizados ratos wistar machos adultos com cerca de 200g de peso corporal divididos em quatro grupos de quatorze animais denominados na seguinte forma: Arginina Treinado (AT), Arginina Sedentário (AS), Dieta-Controle Treinado (CT) e Dieta-Controle Sedentário (CS). Ambas as dietas foram elaboradas com base das recomendações da AIN-93, sendo que a dieta enriquecida com arginina recebeu acréscimo de 2% deste aminoácido e a dieta controle recebeu um mix de aminoácidos não essenciais para garantir que ambas fossem isonitrogenadas e isocalóricas e as proporções de aminoácidos presente nas rações foi conferida por aminograma. O treinamento dos animais consistiu em exercício anaeróbio com sessões que eram compostas de 4 séries de 10 saltos com um minuto de descanso entre estas em tanque de água. Os saltos eram desempenhados com carga de 50% do peso corporal acoplado ao tórax dos animais na freqüência de 5 dias por semana por 6 semanas. A evolução da massa corporal dos animais bem como o consumo de ração foram avaliadas três vezes por semana e estimada uma média semanal. Foram realizados testes de tolerância oral à glicose (OGTT) e tolerância à insulina (ITT) no início e ao final do experimento em todos os animais para avaliar alterações na sensibilidade à insulina. Após 72hs da última sessão de treinamento os animais foram anestesiados para infusão de insulina, coleta dos músculos gastrocnêmio e plantar, fígado, sangue e eutanasiados conforme protocolo aprovado pelo CEA-USP. As análises bioquímicas foram determinações séricas de insulina, GH, IGF-1 e a proteína transportadora de IGF-1 (IGFBP-3), glicose plasmática, uréia e creatinina séricas, IGF-1 muscular e hepático por kits comerciais de tecnologia multiplex Luminex e aminograma sérico por cromatografia. As análises moleculares foram realizadas para as proteínas chaves envolvidas na via de síntese protéica muscular em sua forma total e fosforilada, sendo estas: IRS-1, Akt, mTOR, 4E-BP1 e p70S6K determinadas por método de western blotting. Resultados: Não foram encontradas diferenças estatisticamente significativas nos parâmetros avaliados com exceção da creatinina que se mostrou mais elevada nos grupos suplementados com arginina. A suplementação de arginina, nas concentrações administradas, bem como o exercício de alta intensidade pelo período determinado não foram capazes de alterar a expressão das proteínas envolvidas na regulação de síntese protéica muscular de ratos nem a sensibilidade celular à insulina. Conclusão: não houve aumento da síntese protéica muscular com a suplementação de arginina, nestas condições experimentais. / The arginine is an amino acid conditionally essential that participates in innumerous metabolic reactions in the body like, for instance, the urea cycle, the synthesis of creatine and production of nitric oxide (NO). Besides those functions the arginine is associated, with the insulin sensitivity, GH secretion and most recently with muscle protein synthesis. The aim of this work was to investigate the effect of L-arginine chronic oral supplementation on the muscle protein synthesis, through mTOR pathway, in order to contribute with new scientific discussions about this broad action amino acid. Methods: Wistar male adult rats were used with about 200g body weight distribute into four groups of fourteen animals named this way: Trained Arginine (TA), sedentary Arginine (SA), Trained Diet-Control (TC) and Sedentary Diet-control (SC). Both diets were elaborated based on the AIN-93 recommendations, considering that the enriched diet with arginine was added 2% of this amino acid and the control diet received a mix of non-essential amino acid in order to ensure that both were isonitrogenous and isocaloric and the proportions of present amino acids in the rations have been checked through aminogram. The animals training consisted of anaerobic exercise with sections composed by four jump series, with one minute rest among these in a PVC cube water. The jumps were performed with a load of 50% of their body weight attached in the animal\'s trunk, five days a week over six weeks. The animals\' body weight evolution as well as the food intake were evaluated three times a week in order to figure a weekly average. Oral glucose test tolerance (OGTT) and insulin test tolerance (ITT) have been done in the beginning and in the end of the experiment in all animals to evaluate insulin sensitive changes. The animals were anesthetized to insulin infusion, gastrocnemic and plantaris muscles, liver and blood collects 72 hrs after the last training section and afterwards sacrificed according to CEA-USP approved protocol. The biochemical analysis were blood determination of insulin, GH, IGF-1 and its binding protein 3 (IGFBP-3), glucose, urea and creatinine, and muscle and liver IGF-1 through commercial kits of multiplex Luminex technology and seric aminogram through chromatography. The molecular analysis were performed for the key proteins of the muscle protein synthesis pathway in its total and phosphorylated form: IRS-1, Akt-1, mTOR, 4E-BP1 and p70S6K determined by western blotting method. Results: Significant statistical differences were not found to all evaluated biomarkers in this experiment except for creatinine which was more elevated in groups supplemented with arginine. The arginine supplementation, in these given doses, as well as the high-intense exercise, failed in stimulate both the expression of the proteins involved in the muscle protein synthesis regulation and the insulin sensitivity in the rats in this condition. Conclusion: There hasn\'t been any increase in the muscle protein synthesis with arginine supplementation, in these experimental conditions.

Les travaux de l'équipe ont permis de montrer qu'IL4I1 est une L-amino acide oxydase sécrétée par les cellules d'origine myéloïde dégradant la phénylalanine en H2O2, NH3 et phénylpyruvate. Elle est fortement exprimée au sein des tumeurs humaines et facilite l'échappement tumoral dans un modèle de mélanome murin. Cette enzyme inhibe l'expression de la chaîne ζ du TCR ainsi que la prolifération des lymphocytes T effecteurs/mémoires via la production d'H2O2. IL4I1 appartient donc à une famille d'enzymes régulatrices des réponses immunitaires impliquées dans la défaillance de la réponse anti-tumorale.Au cours de ma thèse, j'ai montré qu'IL4I1 induit la différenciation des lymphocytes T CD4+ naïfs conventionnels en cellules CD25fortFoxP3+ chez l'Homme et la souris. Ces cellules exercent une action suppressive in vitro équivalente à celle de cellules régulatrices obtenues sans IL4I1 et leur phénotype est similaire. La promotion de la différenciation Treg par IL4I1 a pu être observée dans différentes conditions in vitro et s'avère particulièrement importante lorsque les cellules sont cultivées sans ajout d'IL2 et de TGFβ. Le mécanisme impliqué reposerait en partie sur la consommation de Phe par l'activité enzymatique qui serait responsable de l'inhibition de la voie mTORC1 observée.En conclusion, nous avons démontré un nouveau rôle d'IL4I1 sur les lymphocytes T. Ainsi, en inhibant la prolifération des lymphocytes T et en induisant la polarisation Treg, IL4I1 pourrait jouer un rôle important dans l'échappement tumoral. IL4I1 étant sécrétée et peu exprimée à l'état physiologique, elle pourrait être la cible de traitements adjuvants dans le cancer. / Our team has shown that IL4I1 is a secreted L-amino acid oxidase which degrades phenylalanine into H2O2, NH3 and phenylpyruvate.. This enzyme is produced by myeloid cells and expressed within human cancers. IL4I1 expression facilitates tumor growth in a mouse model. IL4I1 inhibits TCRζ chain expression and T lymphocyte proliferation via H2O2 production. Therefore IL4I1 belongs to a family of enzymes endowed with immune regulatory functions involved in the anti-tumor response failure.During my PhD, I showed that IL4I1 induces CD25highFoxP3+ cells differentiation from conventional naïve CD4+ T cells, both in humans and mice in vitro systems. These cells exert similar in vitro suppressive activity than those obtained without IL4I1 with a similar phenotype. Treg differentiation promotion by L4I1 is observed in various in vitro conditions and is particularly important when cells are cultured without addition of IL2 and TGFβ. The involved mechanism would partially depend on the phenylalanine consumption by the enzymatic activity which would be responsible for the mTORC1 pathway inhibition observed.In conclusion, we have demonstrated a new mechanism of IL4I1 action on T lymphocytes. Thus, by inhibiting T lymphocytes proliferation and by inducing Treg polarization, IL4I1 could play an important role in tumor escape. Since IL4I1 is secreted and weakly expressed under physiological conditions, it could be the target of adjuvant therapy in cancer.

mTOR (mammalian target of rapamycin) é uma proteína com papel central no crescimento, na proliferação e na manutenção das células, que participa da formação de dois complexos, mTORC1 e mTORC2. Diversos estudos associam menor atividade de mTOR, em especial o complexo 1, com efeitos protetores contra o envelhecimento e mesmo aumento da expectativa de vida máxima. Alterações no DNA têm sido propostas desde cedo na história dos estudos bioquímicos sobre o envelhecimento como um fator causar da perda de função dos organismos com a idade. Muitos estudos já foram realizados tentando analisar diversos aspectos do acúmulo de alterações no DNA e da capacidade de reparo com a idade. No entanto, a possível relação entre mTOR e reparo de DNA foi muito pouco explorada, em especial em relação ao DNA mitocondrial. Este estudo teve como objetivo avaliar o papel de mTOR na regulação dos níveis de reparo de DNA, em especial da via de reparo por excisão de bases (BER). Os resultados demonstraram que, aparentemente, mTOR surte algum efeito na regulação de duas enzimas da via BER (APE1 e Polγ), além de TFAM, diminuído os níveis das três, tanto no núcleo quanto nas mitocôndrias. No entanto, a atividade de incisão de oligonucleotídeos de APE1 não demonstrou alteração, e indução de apoptose por indução de estresse oxidativo revelou que células com menor expressão de mTOR se encontravam mais resistentes. Adicionalmente, a inibição de mTOR pareceu não alterar o número decópias de DNA mitocondrial e a massa mitocondrial, sugerindo que as células com knockdown de mTOR possuem uma maior reserva respiratória. Em conjunto, os resultados sugerem um possível envolvimento de mTOR na regulação de BER, mesmo que indiretamente, embora não estaja claro por qual via, ou por qual complexo de mTOR / mTOR (mammalian target of rapamycin) is a central protein in the regulation of cell growth, proliferation and maintenance, that participates in the formation of two complexes, mTORC1 and mTORC2. Several studies associate a lower activity of mTOR, especially complex 1, with beneficial effects against aging, and even increased maximum lifespan. DNA alterations have been proposed since the beginnings of the history of the biochemical studies on aging to be a cause of the loss of function that in observed in organisms with age. Several studies have been carried out to analyze several aspects of DNA alterations and DNA repair with age. However, the possible relationship between mTOR and DNA repair has not been explored satisfactorily, especially in relation to mitochondrial DNA. This study had the objective of evaluating the role of mTOR in the regulation of the levels of DNA repair, especially the base excision repair (BER) pathway. The results showed that, apparently, mTOR has some effect in the regulation of two enzymes of the BER pathway (APE1 and Polγ), as well as TFAM, decreasing their levels, both in the nucleus and in the mitochondria. However, APE1 oligonucleotide incision activity was not diminished, and apoptosis induction by methylene blue treatment revealed that cells with mTOR knockdown were more resistant. Addicionally, mTOR inhibition didnt seem to alter mitochondrial DNA copy number and mitochondrial mass, suggesting that mTOR knockdown cells have more respiratory reserve. Takentogether, these results suggest a possible role for mTOR in the regulation of BER, even if indirectly, although it is not clear through which pathway, or which mTOR complex

La voie PI3Kinase/AKT/mTOR, est une cible thérapeutique du temsirolimus, un inhibiteur de mTORC1. Dans le but d'obtenir une inhibition plus importante de cette voie j’utilise dans ce projet deux nouvelles molécules :- le NVP-BEZ 235 (BEZ) qui inhibe à la fois mTORC1 et la PI3kinase- l'AZD8055 (AZD), un inhibiteur des complexes mTORC1 et mTORC2. En utilisant différentes lignées de LCM, j’ai démontré que l'effet de ces nouveaux inhibiteurs sur la survie cellulaire est plus important que celui du temsirolimus. Cela est probablement dû à l'inhibition de la phosphorylation de l'AKT et la 4EBP. La deuxième partie de ce projet étudie la synergie entre les inhibiteurs de m-TOR kinase et l'aracytine. Un effet additif important a été démontré. J’ai trouvé en western blot que l’aracytine inhibe la phosphorylation des substrats de la voie Akt –mTOR notamment le 4EBP. L’ibrutinib (un inhibiteur de la voie Btk) a un effet modeste mais j’ai pu démontrer qu'il est capable à induire une inhibition plus importante de la survie cellulaire lorsqu'il est associé à l’aracytine. Cependant il s'est révélé antagoniste aux inhibiteurs de la voie PI3K-AKT-mTOR, cela reste difficile à décortiquer. Enfin, j’ai trouvé un effet additif de l’ibrutinib en combinaison avec la doxorubicine. Cependant les inhibiteurs de m-TOR n'ont pas le même effet. Afin d’expliquer ces résultats, j’ai étudié l’effet de ces molécules sur l’expression de GSTPi, enzyme de détoxification connue pour avoir un rôle important dans la résistance de LCM à l’anthracycline. J’ai mis en évidence une diminution de l’expression de cet enzyme par l’Ibrutinib. En revanche, les inhibiteurs de mTOR n’ont pas un effet sur l’expression de GSTPi. L’ibrutinib pourrait donc sensibiliser le LCM à l’anthracycline en diminuant l’expression de GSTPi. / The PI3K / AKT / mTOR pathway is the target of Temsirolimus. However, important resistance is observed. We tried to obtain a more important inhibition of PI3K / AKT pathway using two new molecules :- NVP-BEZ 235 (BEZ) which inhibits both mTORC1 and PI3K- AZD8055 (AZD) an inhibitor of mTORC1 and mTORC2 complexes. Using different cell lines of MCL, we have shown that the effect of these new inhibitors on cell survival was more important than that of Temsirolimus. This is probably because contrary to Temsirolimus, the two new molecules can inhibit AKT and 4EBP phosphorylation. In the second part of this project we studied the synergy between the m-TOR kinase inhibitors and aracytine (conventional treatment of MCL). We revealed a significant additive effect in MCL cell lines. We demonstrated by Western blot analysis that aracytine inhibits S6 and 4EBP phosphorylation. This may explain the results obtained from this drug association. We then showed that Ibrutinib (an inhibitor of Btk pathway) can induce a significant inhibition of cell survival when combined with aracytine. In this study, Ibrutinib proved antagonist effect to PI3K-AKT-mTOR inhibitors. The mechanisms of these results remain unclear. Finally, we demonstrated an additive effect of Ibrutinib in combination with doxorubicin. We did not obtain the same results when we combined m-TOR inhibitors with doxorubicin. To explain these data, we studied the effect of these drugs on the expression of GSTPi by western blot. This enzyme is known to have an important role in MCL resistance to anthracycline. Importantly, Ibrutinib induced a decrease in the expression of GSTPi but AZD8055, Temsirolimus and NVP-BEZ235 had no effect.